Tislelizumab is under investigation in clinical trial NCT02660034 (The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Subjects With Advanced Solid Tumors).
⑴用于治疗至少经过二线系统化疗的复发或难治性经典型霍奇金淋巴瘤(R/R cHL)患者。
⑵用于治疗局部晚期或转移性尿路上皮癌。
⑶联合化疗用于治疗一线晚期非鳞状非小细胞肺癌(NSCLC)患者。
⑷用于治疗既往接受过治疗的不可切除肝细胞癌患者。
⑸用于治疗晚期恶性实体瘤
Hôpital Avicenne, Bobigny, France
Hôpital Michallon, Grenoble, France
Institut Paoli Calmette, Marseille, France
Beijing Tsinghua Chang Gung Hospital, Beijing, Beijing, China
Usc Norris Comprehensive Cancer Center (Nccc), Los Angeles, California, United States
Ut Health San Antonio Mays Cancer Center, San Antonio, Texas, United States
Nanyang Central Hospital, Nanyang, Henan, China
Johns Hopkins SKCCC, Baltimore, Maryland, United States
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
Sichuan Cancer Hosiptal, Chengdu, Sichuan, China
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China
Shandong Provincial Hospital Affiliated to Shandong First Medical Universiry, Jinan, Shandong, China
The First Affiliated Hospital of Shandong First Medical University (Shandong Provincial Qianfoshan Hospital), Jinan, Shandong, China
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.